Officials from the Hong Kong Medical and Health Bureau met with a delegation from the State Food and Drug Administration

　　Chinanews.com, Hong Kong, February 14th. Li Xiayin, Acting Director of the Hong Kong Special Administrative Region Government's Medical Services and Health Bureau, met with a delegation led by Zhao Junning, Deputy Director of the State Drug Administration (National Drug Administration) in Hong Kong on the 13th, and exchanged views on issues such as further promoting the development of traditional Chinese medicine. comments and discussions.

　　It is reported that Chen Songqing, Permanent Secretary of the Medical and Health Bureau of the SAR Government, Li Ligang, Deputy Secretary-General, Zhang Weilin, Director of the Development and Planning Office of the Chinese Medicine Hospital, Chen Shangmin, Director of the Division of Chinese Medicine, and Zhao Peiyan, Director of Regulatory Affairs of the Department of Health, also attended the meeting.

　　In addition, the delegation also met with Lin Wenjian, Director of the Department of Health (DH) of the SAR Government.

The Department of Health introduced the regulatory framework and development of Chinese medicine in Hong Kong to the delegation. The two sides had in-depth exchanges and discussions on cooperation in the field of Chinese medicine testing, standard research, and improving the quality and safety of Chinese medicine.

　　Li Xiayin said that the SAR government sincerely appreciates the strong support of the State Food and Drug Administration for the development of Chinese medicine in Hong Kong, including promoting the simplification of the approval process for the registration and sale of traditional Chinese medicines for external use registered in Hong Kong in the Mainland.

The relevant measures will facilitate Hong Kong's proprietary Chinese medicine manufacturers to explore the market, and will also create good conditions for Hong Kong's proprietary Chinese medicines to "go global" in the long run.

This visit to Hong Kong by a delegation from the State Food and Drug Administration will help Hong Kong expand and deepen cooperation with the Mainland in the regulation of traditional Chinese medicines.

　　After the meeting, the delegation also visited the Chinese Medicine Testing Center of the SAR Government located in the Hong Kong Science Park, visited various laboratories and Chinese medicine herbarium and other facilities in the center, and learned about the work of Chinese medicine testing and scientific research.

(over)